View article

BackgroundThe SMART study randomized 5472 human immunodeficiency virus (HIV)–infected patients with CD4⁺ cell counts >350 cells/μL to intermittent antiretroviral therapy (ART; the drug conservation [DC] group) versus continuous ART (the viral supression [VS] group). In the DC group, participants started ART when the CD4⁺ cell count was <250 cells/μL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART

MethodsPatients who were either ART naive (n=249) or who had not been receiving ART for ⩾6 months (n=228) were analyzed. The following clinical outcomes were assessed: (i) opportunistic disease (OD) or death from any cause (OD/death); (ii) OD (fatal or nonfatal); (iii) serious non-AIDS events (cardiovascular, renal, and hepatic disease plus non–AIDS-defining cancers) and non-OD deaths; and (iv) the composite of outcomes (ii) and (iii …